Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.

Human cell - 1 Jul 2024

Yokota Etsuko, Iwai Miki, Ishida Yuta, Yukawa Takuro, Matsubara Masaki, Naomoto Yoshio, Fujiwara Hideyo, Monobe Yasumasa, Haisa Minoru, Takigawa Nagio, Fukazawa Takuya, Yamatsuji Tomoki

Abstract excerpt

Approximately 3-5% of non-small cell lung cancers (NSCLC) harbor ALK fusion genes and may be responsive to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors. There are only a few reports on cell lines with EML4-ALK variant 3 (v3) and tumoroids that can be subject to long-term culture (> 3 months). In this study, we established tumoroids (PDT-LUAD#119) from a patient with lung cancer harboring EML4-ALK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Carcinoma, Squamous Cell

Share to Cell Transformation, Neoplastic

Share to Crizotinib

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38829559
DOI: 10.1007/s13577-024-01085-8
PMCID: PMC11194197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.PMID 38829559Read ↗

Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.Semantic proximity Read ↗

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentitySemantic proximity Read ↗

Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo modelsSemantic proximity Read ↗

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screeningSemantic proximity Read ↗

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicineSemantic proximity Read ↗

Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic targetSemantic proximity Read ↗

An optimized method to culture human primary lung tumor cell spheroidsSemantic proximity Read ↗

Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platformSemantic proximity Read ↗

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugsSemantic proximity Read ↗

Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectoriesSemantic proximity Read ↗

Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platformSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.